Boston Biotech Nova Anchora Raises $23 Million for Topical Collagen VII Gel

Key figures: $23 million equity financing · Led by Viking Global Investors · Lead candidate NvA-021 topical collagen VII gel · FDA Orphan Drug and Rare Pediatric Disease designations already granted

Boston biotechnology company Nova Anchora said Thursday it has closed a $23 million equity financing to push its topical collagen VII therapy for dystrophic epidermolysis bullosa toward a first clinical proof-of-concept study. The GlobeNewswire release, timed for 8 a.m. ET on Nov. 5, 2026, said Viking Global Investors led the round, with participation from DEBRA Research gGmbH, EB Research Partnership, the EB Medical Research Foundation and Cure EB. The financing includes an initial tranche plus additional capital committed if the company hits specified development milestones.

Nova Anchora is developing NvA-021, an investigational topical gel of recombinant human type VII collagen designed to be applied to wounds during routine bandage changes. Dystrophic epidermolysis bullosa, or DEB, is a rare genetic disease in which collagen VII is missing or defective, so even minor friction can blister and open the skin. The company said significant unmet need remains for options that cover more wounds and fit home care.

What the capital will fund

Proceeds are earmarked for scale-up manufacturing, investigational new drug–enabling studies, clinical supply, an IND filing with the U.S. Food and Drug Administration, and the initial clinical proof-of-concept study, according to the release. Nova Anchora said it has already received pre-IND feedback from the FDA. Its collagen VII program holds FDA Orphan Drug and Rare Pediatric Disease designations. NvA-021 remains investigational; safety and efficacy have not been established.

Co-founder and Chief Executive Jason Bhardwaj said the financing “supports a substantial next phase of development, including scale-up manufacturing, IND-enabling studies, and advancing NvA-021 through an initial clinical proof-of-concept study.” Co-founder Dr. Peter Marinkovich, chair of the scientific advisory board and an associate professor of dermatology at Stanford University, said recent advances have changed what clinicians can offer DEB patients but that “patients still face a substantial burden of wounds and daily care.”

The technology is licensed from Stanford. Michael Hund, CEO of EB Research Partnership—the initial philanthropic funder of the underlying Stanford work—said seeing that science near clinical stages is “incredibly meaningful for the EB community.” Martin Steiner of DEBRA Research said the group is continuing its investment as the company moves toward clinical studies.

By the numbers

How this financing sits against other Massachusetts biotech capital news this week:

• $23 million is Nova Anchora’s disclosed equity financing, structured as an initial tranche plus milestone-tied capital.
• Viking Global Investors, which the company said manages more than $56 billion across public and private investments, led the syndicate.
• SEC Form D summaries compiled for Massachusetts over the past month show Watertown’s AI3 Bio reporting $48.3 million sold (filed Nov. 4) and Woburn’s Rgenta Therapeutics reporting $41.9 million sold against a larger offering (filed Nov. 3). Those filings are regulatory disclosures of securities sold; they are not identical to a priced venture round with a named lead, but they show Nova Anchora’s raise arriving in an active stretch for state biotech fundraising.
• The Boston Report’s simple comparison: Nova Anchora’s announced $23 million is about 48% of AI3 Bio’s Form D amount sold and about 55% of Rgenta’s Form D amount sold (TBR calculations from the figures above).

Rare-disease focus and local biotech backdrop

DEB treatments have advanced in recent years, but Nova Anchora’s pitch is a home-stored topical protein meant for caregivers to apply during bandage changes rather than a systemic or surgical approach. That care-setting claim is the company’s description of the product concept; clinical results are not yet available.

The financing adds to a busy autumn for Boston business news in life sciences. Flagship Pioneering’s merger of Cellarity, Etiome and Empress into AI biotech Etcelera, covered in our Oct. 29 Etcelera story, and Vertex Pharmaceuticals’ raised 2026 forecast have kept Seaport and Kendall Square capital flows in the headlines. For ongoing coverage, see the Boston news business section.

Readers should note that Orphan Drug and Rare Pediatric Disease designations are regulatory incentives; they are not approvals to market NvA-021.

Sources

• Nova Anchora / GlobeNewswire, “Nova Anchora Announces $23 Million Financing…,” Nov. 5, 2026
• Nova Anchora company website
• Viking Global Investors
• Massachusetts Form D funding tracker (AI3 Bio, Rgenta filings)